IL-2 Protein Conjugate for Cancer Treatment
Summary
The USPTO published patent application US20260109747A1 on April 23, 2026, covering an IL-2 protein conjugate comprising an alanine residue (Ala), a cysteine residue (Cys*), and two peptide sequences (SEQ A and SEQ B) with at least 94% sequence identity to SEQ ID NO:1 and SEQ ID NO:2 respectively. The application, filed August 22, 2025 under Application No. 19307745, names inventors Nina Gunnarsson, Matiss Maleckis, and David B. Rosen. CPC classifications include C07K 14/55 (interleukins), A61K 47/542 and A61K 47/60 (protein conjugates for therapeutic use), and A61P 35/00 (antineoplastic agents).
“The present invention relates to an IL-2 protein sequence of the formula Ala-SEQ A-Cys*-SEQ B (I), wherein SEQ A has at least 94% sequence identity to SEQ ID NO:1; SEQ B has at least 94% sequence identity to SEQ ID NO:2; Ala is an alanine residue; and Cys* is a cysteine residue; to conjugates thereof and their uses in the treatment of cancer.”
About this source
USPTO classification C07K covers peptides: short amino-acid chains that form the backbone of antibodies, hormones, vaccines, and increasingly a wider class of therapeutic modalities. Every newly published application in C07K lands in this feed, around 175 a month. Applications publish 18 months after filing, so this feed reveals what antibody engineering groups, vaccine developers, and plant biotech researchers were working on in the prior year and a half. Watch this if you compete in biologics, file freedom-to-operate analyses on antibody drug candidates, scout acquisition targets in vaccine platforms, or track protein-based agricultural biotech filings.
What changed
The USPTO published patent application US20260109747A1 on April 23, 2026, disclosing an IL-2 protein conjugate of formula Ala-SEQ A-Cys-SEQ B (I), wherein SEQ A has at least 94% sequence identity to SEQ ID NO:1 and SEQ B has at least 94% sequence identity to SEQ ID NO:2, with Ala being an alanine residue and Cys being a cysteine residue. The application claims conjugates of this IL-2 protein sequence and their therapeutic uses in treating cancer.
Entities seeking to develop IL-2-based cancer therapeutics or protein conjugate therapies should review the application's claimed sequence space and filing date (August 22, 2025) to assess potential freedom-to-operate considerations. Patent applicants in the immunotherapy space should ensure their own sequence claims are differentiated from the disclosed 94% identity thresholds.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Conjugate Comprising an IL-2 Moiety
Application US20260109747A1 Kind: A1 Apr 23, 2026
Inventors
Nina GUNNARSSON, Matiss MALECKIS, David B. ROSEN
Abstract
The present invention relates to an IL-2 protein sequence of the formula Ala-SEQ A-Cys-SEQ B (I), wherein SEQ A has at least 94% sequence identity to SEQ ID NO:1; SEQ B has at least 94% sequence identity to SEQ ID NO:2; Ala is an alanine residue; and Cys is a cysteine residue; to conjugates thereof and their uses in the treatment of cancer.
CPC Classifications
C07K 14/55 A61K 47/542 A61K 47/60 A61P 35/00
Filing Date
2025-08-22
Application No.
19307745
Related changes
Get daily alerts for USPTO Patent Applications - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.